Chronic treatment with ang-(1-7) reverses abnormal reactivity in the corpus cavernosum and normalizes diabetes-induced changes in the protein levels of ACE, ACE2, ROCK1, ROCK2 and omega-hydroxylase in a rat model of type 1 diabetes

Journal of Diabetes Research

Volumn 2014, Issue , 2014, Pages

  Yousif, Mariam H M ^a   Makki, Batoul ^a   El Hashim, Ahmed Z ^a   Akhtar, Saghir ^a   Benter, Ibrahim F ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

[No Author keywords available]

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; ALKANE 1 MONOOXYGENASE; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN[1-7]; ANGIOTENSIN[1-7][7 DEXTRO ALANINE]; CARBACHOL; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIN 1; GLUCOSE; PHENYLEPHRINE; RHO KINASE; RHO KINASE 1; RHO KINASE 2; UNCLASSIFIED DRUG; ANGIOTENSIN I; ANGIOTENSIN I (1-7); CYTOCHROME P450 4A; G PROTEIN COUPLED RECEPTOR; GLUCOSE BLOOD LEVEL; ONCOPROTEIN; PEPTIDE FRAGMENT; PROTO-ONCOGENE PROTEINS C-MAS-1; ROCK1 PROTEIN, RAT; ROCK2 PROTEIN, RAT; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS CAVERNOSUM; DISEASE DURATION; DOSE RESPONSE; GLUCOSE BLOOD LEVEL; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; LONG TERM CARE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANALYSIS; ANIMAL; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DISEASE MODEL; DRUG EFFECTS; ERECTILE DYSFUNCTION; METABOLISM; PENIS; WISTAR RAT;

ANGIOTENSIN I; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CYTOCHROME P-450 CYP4A; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; ERECTILE DYSFUNCTION; MALE; PENIS; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; PROTO-ONCOGENE PROTEINS; RATS; RATS, WISTAR; RECEPTORS, G-PROTEIN-COUPLED; RHO-ASSOCIATED KINASES; STREPTOZOCIN;

EID: 84924922307     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2014/142154     Document Type: Article

References (49)

1. S. Gur, T. C. Peak, P. J. Kadowitz, S. C. Sikka, and W. J. G. Hellstrom, "Review of erectile dysfunction in diabetic animal models, " Current Diabetes Reviews, vol. 10, no. 1, pp. 61-73, 2014.
2. H. Zheng, X. Liu, and K. P. Patel, "Centrally mediated erectile dysfunction in rats with type 1 diabetes: role of angiotensin II and superoxide, " Journal of Sexual Medicine, vol. 10, no. 9, pp. 2165-2176, 2013.
3. K.-E. Andersson, "Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction, " Pharmacological Reviews, vol. 63, no. 4, pp. 811-859, 2011.
4. V. S. Thorve, A. D. Kshirsagar, N. S. Vyawahare, V. S. Joshi, K. G. Ingale, and R. J. Mohite, "Diabetes-induced erectile dysfunction: epidemiology, pathophysiology and management, " Journal ofDiabetes and its Complications, vol. 25, no. 2, pp. 129-136, 2011.
5. T. Scully, "Diabetes in numbers, " Nature, vol. 485, pp. S2-S3, 2012.
6. D. R. Whiting, L. Guariguata, C. Weil, and J. Shaw, "IDFdiabetes Atlas: global estimates of the prevalence of diabetes for 2011 and 2030, " Diabetes Research and Clinical Practice, vol. 94, no. 3, pp. 311-321, 2011.
7. R. A. Fraga-Silva, F. Montecucco, F. Mach, R. A. S. Santos, and N. Stergiopulos, "Pathophysiological role of the renin-angiotensin system on erectile dysfunction, " European Journal of Clinical Investigation, vol. 43, no. 9, pp. 978-985, 2013.
8. I. A. Aytaç, J. B. McKinlay, and R. J. Krane, "The likelyworldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences, " BJU International, vol. 84, no. 1, pp. 50-56, 1999.
9. L. S. Malavige and J. C. Levy, "Erectile dysfunction in diabetes mellitus, " Journal of Sexual Medicine, vol. 6, no. 5, pp. 1232-1247, 2009.
10. D. Price and G. Hackett, "Management of erectile dysfunction in diabetes: an update for 2008, " Current Diabetes Reports, vol. 8, no. 6, pp. 437-443, 2008.
11. K. Decaluwé, B. Pauwels, C. Boydens, and J. van de Voorde, "Treatment of erectile dysfunction: new targets and strategies from recent research, " Pharmacology Biochemistry and Behavior, vol. 121, pp. 146-157, 2014.
12. R. A. Fraga-Silva, F. P. Costa-Fraga, S. Q. Savergnini, et al., "An oral formulation of Angiotensin-(1-7) reverses corpus cavernosum damages induced by Hypercholesterolemia, " Journal of Sexual Medicine, vol. 10, no. 10, pp. 2430-2442, 2013.
13. N. Kilarkaje, M. H. M. Yousif, A. Z. El-Hashim, B. Makki, S. Akhtar, and I. F. Benter, "Role of angiotensin II and angiotensin-(1-7) in diabetes-induced oxidative DNA damage in the corpus cavernosum, " Fertility and Sterility, vol. 100, no. 1, pp. 226-233, 2013.
14. M. H. Yousif, E. O. Kehinde, and I. F. Benter, "Different responses to angiotensin-(1-7) in young, aged and diabetic rabbit corpus cavernosum, " Pharmacological Research, vol. 56, no. 3, pp. 209-216, 2007.
15. L.-M. Jin, "Angiotensin II signaling and its implication in erectile dysfunction, " Journal of Sexual Medicine, vol. 6, no. 3, pp. 302-310, 2009.
16. V. B. Patel, N. Parajuli, and G. Y. Oudit, "Role of angiotensinconverting enzyme 2 (ACE2) in diabetic cardiovascular complications, " Clinical Science, vol. 126, no. 7, pp. 471-482, 2014.
17. R. A. S. Santos, A. J. Ferreira, T. Verano-Braga, and M. Bader, "Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system, " Journal of Endocrinology, vol. 216, no. 2, pp. R1-R17, 2013.
18. I. F. Benter, M. H. M. Yousif, C. Cojocel, M. Al-Maghrebi, and D. I. Diz, "Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction, " American Journal of Physiology: Heart and Circulatory Physiology, vol. 292, no. 1, pp. H666-H672, 2007.
19. M. H. M. Yousif and I. F. Benter, "Role of cytochrome P450 metabolites of arachidonic acid in regulation of corporal smooth muscle tone in diabetic and older rats, " Vascular Pharmacology, vol. 47, no. 5-6, pp. 281-287, 2007.
20. M. H. M. Yousif, I. F. Benter, K. M. J. Dunn, A. J. Dahly-Vernon, S. Akhtar, and R. J. Roman, "Role of 20-hydroxyeicosatetraenoic acid in altering vascular reactivity in diabetes, " Autonomic and Autacoid Pharmacology, vol. 29, no. 1-2, pp. 1-12, 2009.
21. A. C. Da Costa Gonçalves, R. Leite, R. A. Fraga-Silva, et al., "Evidence that the vasodilator angiotensin-(1-7)-Mas axis plays an important role in erectile function, " The American Journal of Physiology-Heart and Circulatory Physiology, vol. 293, no. 4, pp. H2588-H2596, 2007.
22. J. Shi and L. Wei, "Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil, " Journal of Cardiovascular Pharmacology, vol. 62, no. 4, pp. 341-354, 2013.
23. T. J. Bivalacqua, H. C. Champion, M. F. Usta, et al., "RhoA/Rhokinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction, " Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 24, pp. 9121-9126, 2004.
24. A. M. Alsaad, B. N. Zordoky, M. M. Tse, and A. O. El-Kadi, "Role of cytochrome P450-mediated arachidonic acid metabolites in the pathogenesis of cardiac hypertrophy, " Drug Metabolism Reviews, vol. 45, no. 2, pp. 173-195, 2013.
25. F. Fan, C.-W. Sun, K. G. Maier, et al., "20-Hydroxyeicosatetraenoic acid contributes to the inhibition of K+ channel activity and vasoconstrictor response to angiotensin II in rat renalmicrovessels, " PLoS ONE, vol. 8, no. 12, Article IDe82482, 2013.
26. D. L. Kroetz and F. Xu, "Regulation and inhibition of arachidonic acid ω-hydroxylases and 20-HETE formation, " Annual Review of Pharmacology and Toxicology, vol. 45, pp. 413-438, 2005.
27. J. F. Giani, M. M. Gironacci, M. C. Muñoz, D. Turyn, and F. P. Dominici, "Angiotensin-(1-7) has a dual role on growthpromoting signalling pathways in rat heart in vivo by stimulating STAT3 and STAT5a/b phosphorylation and inhibiting angiotensin II-stimulated ERK1/2 and Rho kinase activity, " Experimental Physiology, vol. 93, no. 5, pp. 570-578, 2008.
28. M. M. Muthalif, I. F. Benter, M. R. Uddin, J. L. Harper, and K. U. Malik, "Signal transduction mechanisms involved in angiotensin-(1-7)-stimulated arachidonic acid release and prostanoid synthesis in rabbit aortic smooth muscle cells, " Journal of Pharmacology and Experimental Therapeutics, vol. 284, no. 1, pp. 388-398, 1998.
29. I. F. Benter, M. H. M. Yousif, F. M. Al-Saleh, R. Raghupathy, M. C. Chappell, and D. I. Diz, "Angiotensin-(1-7) blockade attenuates captopril-or hydralazine-induced cardiovascular protection in spontaneously hypertensive rats treated with NG-nitro-l-arginine methyl ester, " Journal of Cardiovascular Pharmacology, vol. 57, no. 5, pp. 559-567, 2011.
30. A. Z. El-Hashim, W. M. Renno, R. Raghupathy, H. T. Abduo, S. Akhtar, and I. F. Benter, "Angiotensin-(1-7) inhibits allergic inflammation, via the MAS1 receptor, through suppression of ERK1/2-and NF-κB-dependent pathways, " British Journal of Pharmacology, vol. 166, no. 6, pp. 1964-1976, 2012.
31. W. M. Renno, A. G. Al-Banaw, P. George, A. A. Abu-Ghefreh, S. Akhtar, and I. F. Benter, "Angiotensin-(1-7) via themas receptor alleviates the diabetes-induced decrease in GFAP and GAP-43 immunoreactivity with concomitant reduction in the COX-2 in hippocampal formation: an immunohistochemical study, " Cellular and Molecular Neurobiology, vol. 32, no. 8, pp. 1323-1336, 2012.
32. S. Akhtar, M. H. Yousif, G. S. Dhaunsi, B. Chandrasekhar, O. Al-Farsi, and I. F. Benter, "Angiotensin-(1-7) inhibits epidermal growth factor receptor transactivation via a Mas receptordependent pathway, " British Journal of Pharmacology, vol. 165, no. 5, pp. 1390-1400, 2012.
33. M. H. M. Yousif, G. S. Dhaunsi, B. M. Makki, B. A. Qabazard, S. Akhtar, and I. F. Benter, "Characterization of Angiotensin-(1-7) effects on the cardiovascular system in an experimental model of Type-1 diabetes, " Pharmacological Research, vol. 66, no. 3, pp. 269-275, 2012.
34. S. Akhtar, M. H. M. Yousif, G. S. Dhaunsi, et al., "Activation of ErbB2 and downstream signalling via Rho kinases and ERK1/2 contributes to diabetes-induced vascular dysfunction, " PLoS ONE, vol. 8, no. 6, Article ID e67813, 2013.
35. M. Bader, "ACE2, angiotensin-(1-7), and Mas:The other side of the coin, " Pflugers Archiv European Journal of Physiology, vol. 465, no. 1, pp. 79-85, 2013.
36. Y. Chen, S. X. Li, L. S. Yao, R. Wang, and Y. T. Dai, "Valsartan treatment reverses erectile dysfunction in diabetic rats, " International Journal of Impotence Research, vol. 19, no. 4, pp. 366-370, 2007.
37. M. T. Abdel Aziz, M. F. El Asmer, T. Mostafa, et al., "Effects of Losartan, HO-1 Inducers or HO-1 inhibitors on erectile signaling in diabetic rats, " Journal of SexualMedicine, vol. 6, no. 12, pp. 3254-3264, 2009.
38. I. Kifor, G. H. Williams, M. A. Vickers, M. P. Sullivan, P. Jodbert, and R. G. Dluhy, "Tissue angiotensin II as a modulator of erectile function. I. Angiotensin peptide content, secretion and effects in the corpus cavernosum, " Journal of Urology, vol. 157, no. 5, pp. 1920-1925, 1997.
39. D. Iusuf, R. H. Henning, W. H. van Gilst, and A. J. M. Roks, "Angiotensin-(1-7): pharmacological properties and pharmacotherapeutic perspectives, " European Journal of Pharmacology, vol. 585, no. 2-3, pp. 303-312, 2008.
40. Z. Ying, L. Jin, T. Palmer, and R. C. Webb, "Angiotensin II up-regulates the leukemia-associated Rho guanine nucleotide exchange factor (RhoGEF), a regulator of G protein signaling domain-containing RhoGEF, in vascular smooth muscle cells, " Molecular Pharmacology, vol. 69, no. 3, pp. 932-940, 2006.
41. A. V. Schofield and O. Bernard, "Rho-associated coiled-coil kinase (ROCK) signaling and disease, " Critical Reviews in Biochemistry and Molecular Biology, vol. 48, no. 4, pp. 301-316, 2013.
42. J. L. Hannan, M. Albersen, O. Kutlu, et al., "Inhibition of Rhokinase improves erectile function, increases nitric oxide signaling and decreases penile apoptosis in a rat model of cavernous nerve injury, " Journal of Urology, vol. 189, no. 3, pp. 1155-1161, 2013.
43. M. C. Cho, K. Park, J. S. Chai, S. H. Lee, S. W. Kim, and J. S. Paick, "Involvement of sphingosine-1-Phosphate/RhoA/Rho-Kinase signaling pathway in corporal fibrosis following cavernous nerve injury inmale rats, " Journal of Sexual Medicine, vol. 8, no. 3, pp. 712-721, 2011.
44. H. A. Toque, K. P. Nunes, L. Yao, et al., "Activated rho kinase mediates diabetes-induced elevation of vascular arginase activation and contributes to impaired corpora cavernosa relaxation: possible involvement of p38 MAPK activation, " Journal of Sexual Medicine, vol. 10, no. 6, pp. 1502-1515, 2013.
45. M. H. M. Yousif, I. F. Benter, and R. J. Roman, "Cytochrome P450 metabolites of arachidonic acid play a role in the enhanced cardiac dysfunction in diabetic rats following ischaemic reperfusion injury, " Autonomic and Autacoid Pharmacology, vol. 29, no. 1-2, pp. 33-41, 2009.
46. M. H. M. Yousif and I. F. Benter, "Role of 20-hydroxyeicosatetraenoic and epoxyeicosatrienoic acids in the regulation of vascular function in a model of hypertension and endothelial dysfunction, " Pharmacology, vol. 86, no. 3, pp. 149-156, 2010.
47. I. F. Benter, M. H. Yousif, H. Canatan, and S. Akhtar, "Inhibition of Ca2+/calmodulin -dependent protein kinase II, RASGTPase and 20-hydroxyeicosatetraenoic acid attenuates the development of diabetes-induced vascular dysfunction in the rat carotid artery, " Pharmacological Research, vol. 52, no. 3, pp. 252-257, 2005.
48. I. F. Benter, I. Francis, C. Cojocel, J. S. Juggi, M. H. M. Yousif, and H. Canatan, "Contribution of cytochrome P450metabolites of arachidonic acid to hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME, " Autonomic and Autacoid Pharmacology, vol. 25, no. 4, pp. 143-154, 2005.
49. A. C. da Costa Gonçalves, R. A. Fraga-Silva, R. Leite, and R. A. S. Santos, "AVE 0991, a non-peptide Mas-receptor agonist, facilitates penile erection, " Experimental Physiology, vol. 98, no. 3, pp. 850-855, 2013.